116例表皮生长因子受体抑制剂致非小细胞肺癌患者皮肤不良反应分析  

Analysis of Cutaneous Adverse Drug Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in 116 Patients with Non Small Cell Lung Cancer

作　　者：韩姗姗 蔡靖 马进安[3] HAN Shanshan;CAI Jing;MA Jin’an(Department of Dermatology,Geriatric Hospital of Nanjing Medical University&Jiangsu Province Official Hospital,Nanjing 210024,China;Department of Pharmacy,Geriatric Hospital of Nanjing Medical University&Jiangsu Province Official Hospital,Nanjing 210024,China;Department of Oncology,the Second Xiangya Hospital of Central South University,Changsha 410011,China)

机构地区：[1]南京医科大学附属老年医院、江苏省省级机关医院皮肤科,南京210024 [2]南京医科大学附属老年医院、江苏省省级机关医院药学部,南京210024 [3]中南大学湘雅二医院肿瘤科,长沙410011

出　　处：《药学与临床研究》2023年第5期458-461,共4页Pharmaceutical and Clinical Research

摘　　要：目的:分析非小细胞肺癌(NSCLC)患者应用表皮生长因子受体抑制剂(EGFRIs)诱导的皮肤不良反应(CADRs)情况及与肿瘤治疗反应之间的关系。方法:回顾性分析116例2021年1月~2022年12月接受EGFRIs治疗的NSCLC患者病历资料,如用药时间、CADRs和治疗反应等。分析CADRs与治疗反应之间的关系。结果:各药发生CADRs比例分别为奥希替尼93.2%(41/44)、安罗替尼74.4%(29/39)、阿美替尼84.4%(28/33)。所有患者中最常见的不良反应是甲沟炎56例(48.3%),其余依次为痤疮样皮疹46例(39.7%)、红斑脱屑43例(37.1%)、黏膜炎31例(26.7%)、干燥症14例(12.1%)和毛发异常13例(11.2%)。治疗有效的患者,其CADRs发生率更高,差异有统计学意义(P<0.05)。结论:在接受EGFRIs治疗的NSCLC患者人群中,CADRs发生率较高。EGFRIs所致CADRs严重程度与其疗效可能存在关联。Objective:To observe the cutaneous adverse drug reactions(CADRs)induced by epidermal growth factor receptor inhibitors in patients with non small cell lung cancer,and then analyze the relationship between CADRs and tumor therapeutic response.Methods:Retrospective statistical analysis was conducted on the medical records and nursing records,such as medication duration,CADRs and tumor treatment responses,of 116 non small cell lung cancer patients who received treatment with epidermal growth factor receptor inhibitors in hospital from January 2021 to December 2022.Results:Of the 44 cases using oxitinib,41 cases(93.2%)developed CADRs.Of the 39 patients who used arotinib,29 cases(74.4%)developed CADRs.Of the 33 patients who used ametinib,28 cases(84.4%)developed CADRs.The most common adverse reactions among all patients were paronychia in 56 cases(48.3%),followed by acne like rash in 46 cases(39.7%),macular papules in 43 cases(37.1%),mucositis in 31 cases(26.7%),xerosis in 14 cases(12.1%)and hair changes in 13 cases(11.2%).Patients with effective treatment had a higher incidence of CADRs,with a statistically significant difference(P<0.05).Conclusion:CADRs are common among patients with NSCLC treated with epidermal growth factor receptor inhibitors,and there may be a correlation between the severity of CADRs and their efficacy of EGFRIs.

关 键 词：EGFR抑制剂 皮肤不良反应 治疗反应 

分 类 号：R969.3[医药卫生—药理学]